About Inactive serine protease 54
Inactive serine protease 54 (PRSS54) is a protein
from Homo sapiens identified by UniProt accession
Q6PEW0, 395 residues long.
MolForge cross-references it against 0 known binders and
64 disease associations.
Target properties
| Protein name | Inactive serine protease 54 |
| UniProt accession | Q6PEW0 |
| Gene | PRSS54 |
| Organism | Homo sapiens |
| Length | 395 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (64)
Diseases linked to this target (Open Targets).
- azoospermia · score 0.10
- male infertility with teratozoospermia due to single gene mutation · score 0.08
- drug use measurement · score 0.07
- partial chromosome Y deletion · score 0.06
- spermatogenic failure 20 · score 0.06
- spermatogenic failure 72 · score 0.06
- spermatogenic failure 46 · score 0.06
- spermatogenic failure 27 · score 0.06
- spermatogenic failure 18 · score 0.06
- spermatogenic failure 42 · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q6PEW0-F1 | alphafold | PREDICTED | 67.41 | — |
Amino-acid sequence (395 residues)
MVSAAGLSGD GKMRGVLLVL LGLLYSSTSC GVQKASVFYG PDPKEGLVSS MEFPWVVSLQ DSQYTHLAFG CILSEFWVLS IASAIQNRKD IVVIVGISNM DPSKIAHTEY PVNTIIIHED FDNNSMSNNI ALLKTDTAMH FGNLVQSICF LGRMLHTPPV LQNCWVSGWN PTSATGNHMT MSVLRKIFVK DLDMCPLYKL QKTECGSHTK EETKTACLGD PGSPMMCQLQ QFDLWVLRGV LNFGGETCPG LFLYTKVEDY SKWITSKAER AGPPLSSLHH WEKLISFSHH GPNATMTQKT YSDSELGHVG SYLQGQRRTI THSRLGNSSR DSLDVREKDV KESGRSPEAS VQPLYYDYYG GEVGEGRIFA GQNRLYQPEE IILVSFVLVF FCSSI
Explore Inactive serine protease 54 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets